Imugene Limited

Imugene announces Updated Phase 1b HER-Vaxx data presented at ASCO

04/06/2019 15:42:00

SYDNEY, Australia, 4 June 2019: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced positive data from the ongoing patients in the Phase Ib study of its HER-Vaxx cance…

Imugene announces Updated Phase Ib HER-Vaxx data

04/06/2019 09:27:00

SYDNEY, Australia, 4 June 2019: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced positive data from the ongoing patients in the Phase Ib study of its HER-Vaxx cance…

Imugene announce Global Biotechnology and Venture Capital Executive Joins Imugene Board

20/05/2019 12:13:00

SYDNEY Australia 20 May 2019: The Board of Imugene Limited today announced the appointment of leading biotechnology executive and entrepreneur Dr Jens Eckstein as a Non-Executive Director, effective 2…

Company Presentations / by - 23 days ago

Imugene (ASX:IMU) Presentation, FNN Investor Event, May 2019, Sydney

27 May 2019 - Imugene Limited (ASX:IMU) Managing Director & CEO, Leslie Chong presents on trial progress with the company's HER-B Vaxx cancer vaccines, the advantages of B-cell vac…

Interviews / by Anna Napoli - 23 days ago

Imugene (ASX:IMU) targeting gastric cancer

27 May 2019 - Imugene Limited (ASX:IMU) Managing Director & CEO, Leslie Chong discusses trial progress with the company's HER-B Vaxx cancer vaccines, the advantages of B-cell vacci…

Company News / by Rachael Jones - A month ago

Imugene’s HER-Vaxx to be presented at US oncology meeting

29 Apr 2019 - Immuno-oncology company Imugene (ASX:IMU) will present data from its Phase Ib study of its HER-Vaxx cancer vaccine at the prestigious American Society of Clinical Onc…

Company News / by Rachael Jones - A month ago

Imugene appoints Dr Lesley Russell to the board

23 Apr 2019 - Immuno-oncology company Imugene (ASX:IMU) has appointed Dr Lesley Russell as a Non-Executive Director, a leading global pharmaceutical executive.

Company News / by Rachael Jones - 2 months ago

Imugene presents new data on cancer vaccines AACR

02 Apr 2019 - Biotech company Imugene (ASX:IMU) presented new data on the KEY-Vaxx and B-Vaxx cancer vaccine programs at the American Association for Cancer Research Annual Meeting…

Market Reports / by Katrina Bullock - 2 months ago

Linius Technologies displays new blockchain tech: Aus shares 0.9% higher at noon

22 Mar 2019 - The S&P/ASX 200 opened higher this morning following strong leads from Wall Street where US equities reached a five-month high. The market continues to rally into the…

Company News / by Rachael Jones - 3 months ago

Imugene doses first patient in Moldova with cancer vaccine

14 Mar 2019 - Immuno-oncology company Imugene (ASX:IMU) has dosed the first patient in Moldova in Eastern Europe for the treatment of HER-2 positive gastric cancer.

Company News / by Anna Napoli - 5 months ago

Imugene appoints distinguished scientist to SAB

07 Jan 2019 - Imugene (ASX:IMU) has today announced the appointment of distinguished scientist, Dr Michael Caligiuri to its Scientific Advisory Board.

Company Presentations / by - 7 months ago

Imugene (ASX:IMU) Presentation, FNN Investor Event, October 2018, Sydney

26 Oct 2018 - Imugene Limited (ASX:IMU) Managing Director and CEO, Leslie Chong presents on the company's trial progress with its lead HER-Vaxx cancer vaccine, advantages of B-cell…

Interviews / by Rachael Jones - 7 months ago

Imugene (ASX:IMU) targeting gastric cancer

29 Oct 2018 - Imugene Limited (ASX:IMU) Managing Director and CEO, Leslie Chong talks trial progress with the company's lead HER-Vaxx cancer vaccine, advantages of B-cell vaccines …

Market Reports / by Rachael Jones - 8 months ago

Healthcare sector stays in the green: ASX closes 0.6% lower

01 Oct 2018 - It's been a quiet day on the markets with the ASX closing lower. New Zealand software company Xero did well today, Nufarm shares were down. The Canadian dollar and Me…

Company News / by Anna Napoli - 8 months ago

Imugene appoints leading cancer researcher to board

01 Oct 2018 - Biotech company, Imugene (ASX:IMU) has today announced the appointment of a leading cancer researcher to its Scientific Advisory Board.

Company News / by Rachael Jones - 8 months ago

Imugene starts manufacture of KEY-Vaxx for trials

21 Sep 2018 - Clinical stage immuno-oncology company Imugene (ASX:IMU) has formally commenced cGMP manufacture of the clinical batch of cancer vaccine KEY-Vaxx.

Company News / by Anna Napoli - 9 months ago

Imugene completes recruitment for Phase 1b clinical trial of HER-Vaxx

11 Sep 2018 - Immuno-oncology company, Imugene (ASX:IMU) has announced the Phase 1b clinical trial of its cancer vaccine (HER-Vaxx) for gastric cancer patients has completed recrui…

Market Reports / by Jessica Amir - A year ago

Out of puff on Friday: Aus shares close 0.9% higher on week

08 Jun 2018 - Market Wrap. ASX20, ASX50, ASX100 and ASX200 reshuffled with Afterpay Touch (ASX:APT) & Kidman Resources (ASX:KDR) in ASX200. MMJ PhyoTech (ASX:MMJ) pleased Canada cl…

Interviews / by Rachael Jones - A year ago

Imugene (ASX:IMU) 1H18 results & outlook

09 March 2018 - Imugene Limited (ASX:IMU) CEO Leslie Chong talks 1H18 and outlook, including progress with the company's lead HER-Vaxx cancer vaccine.

Company News / by Kathy Skantzos - A year ago

Imugene raises $8.7 million for clinical trial

23 Nov 2017 - Immune-oncology company Imugene (ASX:IMU) raises $8.7 million through a $6.7 million institutional placement and a $2 million fully underwritten entitlement offer.

Company Presentations / by - A year ago

Imugene (ASX:IMU) Presentation, FNN Small Cap Investor Event, October 2017, Sydney

12 Oct 2017 - Imugene Limited (ASX:IMU) CEO Leslie Chong presents at the FNN Small Cap Investor Event, October 2017, Sydney.

Interviews / by Jessica Amir - A year ago

Imugene (ASX:IMU) talks Phase 1 & 2 cancer trials

11 Oct 2017 - Imugene Limited (ASX:IMU) CEO Leslie Chong talks cancer trials for the company's lead drug candidate, HER-Vaxx, strategy and outlook.

Market Reports / by - 3 years ago

Market Wrap: Aus shares close 0.48% lower

04 Jan 2016 - Aus shares close 0.48% lower. Amaysim Australia Limited (ASX:AYS) acquires mobile virtual network operator Vaya.

Company News / by - 4 years ago

Imugene Vaxx shows dramatic improvement

20 Apr 2015 - Imugene Limited (ASX:IMU) says leading cancer vaccination is showing a dramatic ten-fold increase in antibodies and has met an additional milestone.

Market Reports / by - 4 years ago

Midday: ASX follows global selloff

08 Oct 2014 - ASX follows global selloff. BC Iron Limited (ASX:BCI) increases its relevant interest in Iron Ore Holdings to 90.37%.